SAN DIEGO, CALGARY - Oncolytics Biotech Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Thursday, May 9, 2024, at 4:30 p.m. ET to discuss a corporate update and financial results for the first quarter 2024.

Conference Call & Webcast

Date: Thursday, May 9, 2024

Time: 4:30 p.m. ET

Dial In - North American Toll-Free: (800) 836-8184

Dial In - International: (289) 819-1350

Conference ID (if needed): 77797

A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialing (888) 660-6345 (North America) or (289) 819-1450 (International) and using replay code: 77797#.

About Oncolytics Biotech Inc.

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and Phase 1 and 2 studies in pancreatic cancer. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype - turning 'cold' tumors 'hot' - through innate and adaptive immune responses to treat a variety of cancers.

Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer, both of which have received Fast Track designation from the FDA.

Contact:

Jon Patton

Email: jpatton@oncolytics.ca

Timothy McCarthy

Tel: +1-917-679-9282

Email: tim@lifesciadvisors.com

(C) 2024 Electronic News Publishing, source ENP Newswire